Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 + Bevacizumab in Recurrent Glioblastoma
NCT01933815Phase 2Suspended
- Sponsor
- Cortice Biosciences Inc.
- Start
- Aug 2013
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abeotaxane in glioblastoma (GBM), sponsored by Cortice Biosciences Inc.. Started Aug 2013; status: suspended.
02
Drugs
abeotaxane
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01933815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933815.